AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
EFFECT OF POSTMENOPAUSAL HORMONE-THERAPY ON GLUCOSE AND INSULIN CONCENTRATIONS
Authors: ESPELAND MA HOGAN PE FINEBERG SE HOWARD G SCHROTT H WACLAWIW MA BUSH TL
Citation: Ma. Espeland et al., EFFECT OF POSTMENOPAUSAL HORMONE-THERAPY ON GLUCOSE AND INSULIN CONCENTRATIONS, Diabetes care, 21(10), 1998, pp. 1589-1595
INTRAPORTAL VS KIDNEY SUBCAPSULAR SITE FOR HUMAN PANCREATIC-ISLET TRANSPLANTATION
Authors: JINDAL RM SIDNER RA MCDANIEL HB JOHNSON MS FINEBERG SE
Citation: Rm. Jindal et al., INTRAPORTAL VS KIDNEY SUBCAPSULAR SITE FOR HUMAN PANCREATIC-ISLET TRANSPLANTATION, Transplantation proceedings, 30(2), 1998, pp. 398-399
INSULIN, C-PEPTIDE AND PROINSULIN LEVELS USING NEW AND OLD DIAGNOSTIC-CRITERIA THE ELDERLY
Authors: FINEBERG SE BARRETTCONNOR E FINEBERG NS
Citation: Se. Fineberg et al., INSULIN, C-PEPTIDE AND PROINSULIN LEVELS USING NEW AND OLD DIAGNOSTIC-CRITERIA THE ELDERLY, Diabetes, 47, 1998, pp. 611-611
THE POSTMENOPAUSAL ESTROGEN PROGESTIN INTERVENTIONS STUDY - PRIMARY OUTCOMES IN ADHERENT WOMEN/
Authors: BARRETTCONNOR E SLONE S GREENDALE G KRITZSILVERSTEIN D ESPELAND M JOHNSON SR WACLAWIW M FINEBERG SE
Citation: E. Barrettconnor et al., THE POSTMENOPAUSAL ESTROGEN PROGESTIN INTERVENTIONS STUDY - PRIMARY OUTCOMES IN ADHERENT WOMEN/, Maturitas, 27(3), 1997, pp. 261-274
WHITHER LIPOPROTEIN(A) - IS THIS LIPID SUBCLASS A CAUSATIVE OR PREDICTIVE FACTOR IN DIABETIC MACROVASCULAR DISEASE
Authors: FINEBERG SE
Citation: Se. Fineberg, WHITHER LIPOPROTEIN(A) - IS THIS LIPID SUBCLASS A CAUSATIVE OR PREDICTIVE FACTOR IN DIABETIC MACROVASCULAR DISEASE, Diabetes care, 20(8), 1997, pp. 1225-1227
SOME THINGS OLD, SOME THINGS NEW
Authors: CLARK CM BARON A FINEBERG SE FREIDENBERG G MARRERO D ORR DP PRINCE M WEINBERGER M WHEELER M REYNOLDS L
Citation: Cm. Clark et al., SOME THINGS OLD, SOME THINGS NEW, Diabetes care, 20(1), 1997, pp. 1-1
EFFECT OF POSTMENOPAUSAL HORMONE-THERAPY ON BODY-WEIGHT AND WAIST ANDHIP GIRTHS
Authors: ESPELAND MA STEFANICK ML KRITZSILVERSTEIN D FINEBERG SE WACLAWIW MA JAMES MK GREENDALE GA
Citation: Ma. Espeland et al., EFFECT OF POSTMENOPAUSAL HORMONE-THERAPY ON BODY-WEIGHT AND WAIST ANDHIP GIRTHS, The Journal of clinical endocrinology and metabolism, 82(5), 1997, pp. 1549-1556
WHY DO IDDM AND NIDDM PATIENTS DIFFER IN THEIR IMMUNE-RESPONSES TO INSULIN THERAPY
Authors: FINEBERG NS FINEBERG SE GALLOWAY JA ANDERSON JH
Citation: Ns. Fineberg et al., WHY DO IDDM AND NIDDM PATIENTS DIFFER IN THEIR IMMUNE-RESPONSES TO INSULIN THERAPY, Diabetologia, 39, 1996, pp. 339-339
CAN INSULIN PHARMACOKINETICS BE ACCURATELY ASSESSED USING STORED SERACONTAINING ANTIINSULIN ANTIBODIES
Authors: FINEBERG SE WOODWORTH J ANDERSON JA HUFFERD S GIBSON R FINEBERG NS
Citation: Se. Fineberg et al., CAN INSULIN PHARMACOKINETICS BE ACCURATELY ASSESSED USING STORED SERACONTAINING ANTIINSULIN ANTIBODIES, Diabetologia, 39, 1996, pp. 807-807
IS IT AGE OR INSULIN-SECRETION THAT MODULATES THE INSULIN IMMUNE-RESPONSE
Authors: FINEBERG NS FINEBERG SE GALLOWAY JA ANDERSON JH
Citation: Ns. Fineberg et al., IS IT AGE OR INSULIN-SECRETION THAT MODULATES THE INSULIN IMMUNE-RESPONSE, Diabetes, 45, 1996, pp. 965-965
WHEN SHOULD CARBOHYDRATE-METABOLISM BE CONSIDERED DISORDERED IN AN AGING POPULATION
Authors: FINEBERG SE FINEBERG NS BARRETTCONNOR E
Citation: Se. Fineberg et al., WHEN SHOULD CARBOHYDRATE-METABOLISM BE CONSIDERED DISORDERED IN AN AGING POPULATION, Diabetes, 45, 1996, pp. 1041-1041
DO OBESE TYPE-2 PATIENTS HAVE DEFECTIVE REGULATION OF LEPTIN
Authors: FINEBERG SE GIBSON RG HUFFERD S
Citation: Se. Fineberg et al., DO OBESE TYPE-2 PATIENTS HAVE DEFECTIVE REGULATION OF LEPTIN, Diabetes, 45, 1996, pp. 1239-1239
GESTATIONAL DIABETES - A PART OF THE INSULIN-RESISTANCE SYNDROME
Authors: PORTER B AMERMAN B CLARK CM QIU CF MOORE P FINEBERG N FINEBERG SE ALDASOUQI S
Citation: B. Porter et al., GESTATIONAL DIABETES - A PART OF THE INSULIN-RESISTANCE SYNDROME, Diabetes, 45, 1996, pp. 1254-1254
IMMUNOLOGICAL EFFECTS OF INSULIN LISPRO [LYS (B28), PRO (B29) HUMAN INSULIN] IN IDDM AND NIDDM PATIENTS PREVIOUSLY TREATED WITH INSULIN
Authors: FINEBERG NS FINEBERG SE ANDERSON JH BIRKETT MA GIBSON RG HUFFERD S
Citation: Ns. Fineberg et al., IMMUNOLOGICAL EFFECTS OF INSULIN LISPRO [LYS (B28), PRO (B29) HUMAN INSULIN] IN IDDM AND NIDDM PATIENTS PREVIOUSLY TREATED WITH INSULIN, Diabetes, 45(12), 1996, pp. 1750-1754
ACCURACY AND PRECISION OF THE MEDISENSE-PRECISION-G BLOOD-GLUCOSE TESTING SYSTEM
Authors: ZAMOTH D CEMBROWSKI G MCNEIL L FINEBERG SE GIBSON R
Citation: D. Zamoth et al., ACCURACY AND PRECISION OF THE MEDISENSE-PRECISION-G BLOOD-GLUCOSE TESTING SYSTEM, Clinical chemistry, 42(6), 1996, pp. 250-250
CONTROLLED PORTIONS OF PRESWEETENED CEREALS PRESENT NO GLYCEMIC PENALTY IN PERSONS WITH INSULIN-DEPENDENT DIABETES-MELLITUS
Authors: WHEELER ML FINEBERG SE GIBSON R FINEBERG N
Citation: Ml. Wheeler et al., CONTROLLED PORTIONS OF PRESWEETENED CEREALS PRESENT NO GLYCEMIC PENALTY IN PERSONS WITH INSULIN-DEPENDENT DIABETES-MELLITUS, Journal of the American Dietetic Association, 96(5), 1996, pp. 458-463
EFFECTS OF ESTROGEN OR ESTROGEN PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL/
Authors: MILLER VT LAROSA J BARNABEI V KESSLER C LEVIN G SMITHROTH A GRIFFIN M STOY DB BUSH T ZACUR H FOSTER D ANDERSON J MCKENZIE A MILLER S WOOD PD STEFANICK ML MARCUS R AKANA A HEINRICHS L KIRCHNER C OHANLAN K RUYLE M SHEEHAN M JUDD HL GREENDALE G BAYALOS R LOZANO K KAWAKAMI K BARRETTCONNOR E LANGER R KRITZSILVERSTEIN D CARRIONPETERSEN ML CAVERO C SCHROTT HG JOHNSON SR FEDDERSEN DA KRUTZFELDT DL BENDA JA PAUERSTEIN C TRABAL J SCHENKEN R STERN MP RODRIGUEZSIFUENTES M EASTON C WELLS HB ESPELAND M HOWARD G BYINGTON R LEGAULT C SHUMAKER S HOGAN P HIRE D WASILAUSKAS C JAMES M LANE K TERRELL T REECE S PIERCE J SNOW M ANTHONY S MEBANESIMS IL EINHORN P HUNSBERGER S WACLAWIW M LIPPEL K LUCAS D VERTER J JACKSON S KELAGHAN J PERLMAN J WOLF P MCGOWAN J GORDON S HEYSE S FRADKIN J SHERMAN S PAGE L SORENSON A HULKA B BRODY B BURKMAN R HEANEY R KRAUSS R ROBERTS H WITTES J RIGGS L MOSS R ALBERS J MARCOVINA S FINEBERG SE TRACY RP MERINO M SCULLY R LIVOLSI V KESSLER G
Citation: Vt. Miller et al., EFFECTS OF ESTROGEN OR ESTROGEN PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL/, JAMA, the journal of the American Medical Association, 273(3), 1995, pp. 199-208
INSULIN AUTOIMMUNE SYNDROME AS A CAUSE OF SPONTANEOUS HYPOGLYCEMIA INALCOHOLIC CIRRHOSIS
Authors: SHAH P MARES D FINEBERG SE PESCOVITZ M FILO R JINDAL R MAHONEY S LUMENG L
Citation: P. Shah et al., INSULIN AUTOIMMUNE SYNDROME AS A CAUSE OF SPONTANEOUS HYPOGLYCEMIA INALCOHOLIC CIRRHOSIS, Gastroenterology, 109(5), 1995, pp. 1673-1676
INSULIN IMMUNE-RESPONSE TO LYSPRO HUMAN INSULIN THERAPY IN INSULIN NAIVE TYPE-I AND TYPE-II PATIENTS
Authors: FINEBERG SE FINEBERG NS ANDERSON JH BIRKETT M
Citation: Se. Fineberg et al., INSULIN IMMUNE-RESPONSE TO LYSPRO HUMAN INSULIN THERAPY IN INSULIN NAIVE TYPE-I AND TYPE-II PATIENTS, Diabetologia, 38, 1995, pp. 4-4
PRESWEETENED CEREALS PRESENT NO GLYCEMIC PENALTY IN IDDM
Authors: WHEELER ML FINEBERG SE GIBSON R FINEBERG N
Citation: Ml. Wheeler et al., PRESWEETENED CEREALS PRESENT NO GLYCEMIC PENALTY IN IDDM, Diabetes, 44, 1995, pp. 7-7
DOES THE USE OF SHORT-ACTING (LYSPRO) HUMAN INSULIN IN INSULIN NAIVE PATIENTS AUGMENT THE INSULIN IMMUNE-RESPONSE OR DIFFER BETWEEN TYPE-I AND TYPE-II PATIENTS
Authors: FINEBERG SE FINEBERG NS ANDERSON JH BIRKETT M
Citation: Se. Fineberg et al., DOES THE USE OF SHORT-ACTING (LYSPRO) HUMAN INSULIN IN INSULIN NAIVE PATIENTS AUGMENT THE INSULIN IMMUNE-RESPONSE OR DIFFER BETWEEN TYPE-I AND TYPE-II PATIENTS, Diabetes, 44, 1995, pp. 231-231
ACCURACY OF A RAPID, QUANTITATIVE BEDSIDE BETA-HYDROXYBUTYRATE TEST SYSTEM
Authors: GIBSON RG FINEBERG SE BRIDGES JM
Citation: Rg. Gibson et al., ACCURACY OF A RAPID, QUANTITATIVE BEDSIDE BETA-HYDROXYBUTYRATE TEST SYSTEM, Clinical chemistry, 41(6), 1995, pp. 193-194
DOES LYSPRO (B28,29) HUMAN INSULIN ANALOG HAVE ALTERED IMMUNOGENICITYIN PATIENTS WITH TYPE-1 DIABETES
Authors: FINEBERG NS FINEBERG SE ANDERSON JH BIRKETT M GIBSON RG HUFFERD S
Citation: Ns. Fineberg et al., DOES LYSPRO (B28,29) HUMAN INSULIN ANALOG HAVE ALTERED IMMUNOGENICITYIN PATIENTS WITH TYPE-1 DIABETES, Diabetologia, 37, 1994, pp. 10000167-10000167
COMPARATIVE IMMUNOGENICITY OF LYSPRO (B28,29) HUMAN INSULIN ANALOG BETWEEN TYPE-I AND TYPE-II PATIENTS
Authors: FINEBERG SE FINEBERG NS ANDERSON JH BIRKETT M GIBSON RG HUFFERD S
Citation: Se. Fineberg et al., COMPARATIVE IMMUNOGENICITY OF LYSPRO (B28,29) HUMAN INSULIN ANALOG BETWEEN TYPE-I AND TYPE-II PATIENTS, Diabetologia, 37, 1994, pp. 10000168-10000168
CAN INCREMENTS IN INSULIN LEVELS WITH PROGRESSIVE CARBOHYDRATE INTOLERANCE BE EXPLAINED ON THE BASIS OF HYPERPROINSULINE-MIA
Authors: FINEBERG SE BARRETTCONNOR E HUFFERD S BOWSHER R FINEBERG NS
Citation: Se. Fineberg et al., CAN INCREMENTS IN INSULIN LEVELS WITH PROGRESSIVE CARBOHYDRATE INTOLERANCE BE EXPLAINED ON THE BASIS OF HYPERPROINSULINE-MIA, Diabetes, 43, 1994, pp. 10000158-10000158
Risultati: 1-25 | 26-28